BioCentury | Mar 19, 2012
Strategy

Remaking Merck Serono

...non-CTCL Ph III (CTCL); Ph II (non-CTCL) Returned rights in 2007; Genmab out- licensed to TenX Biopharma Inc....
BioCentury | Jun 13, 2011
Company News

Emergent BioSolutions, TenX Biopharma deal

...Emergent received exclusive, worldwide rights to zanolimumab from TenX Biopharma for infectious, cancer and autoimmune indications. TenX...
...under a 2010 deal (see BioCentury, Feb. 8, 2010). Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. TenX BioPharma Inc....
BioCentury | Nov 8, 2010
Strategy

Networking antibodies

...zanolimumab was the oldest and most expensive in use at Genmab. In February, Genmab granted TenX Biopharma Inc....
...NASDAQ:PDLI), Incline Village, Nev. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. TenX Biopharma Inc....
BioCentury | Sep 20, 2010
Clinical News

Zanolimumab: Phase II data

...develop and commercialize zanolimumab from Genmab (see BioCentury, Feb. 8). Genmab A/S (CSE:GEN), Copenhagen, Denmark TenX Biopharma Inc....
BioCentury | Sep 13, 2010
Clinical News

Zanolimumab: Phase III resumed

...and commercialize zanolimumab earlier this year (see BioCentury, Feb. 8). Genmab A/S (CSE:GEN), Copenhagen, Denmark TenX Biopharma Inc....
BioCentury | May 24, 2010
Clinical News

Zanolimumab: Phase II start

...Laboratories Inc. (San Diego, Calif.) markets Proleukin in the U.S. Genmab A/S (CSE:GEN), Copenhagen, Denmark TenX Biopharma Inc....
BioCentury | Feb 8, 2010
Finance

Regulatory milestones

...Pulmagen (see B2) . Genmab A/S (CSE:GEN) lost DKK0.45 to DKK97.50 last week after granting TenX Biopharma Inc....
BioCentury | Feb 8, 2010
Company News

Genmab, TenX Biopharma deal

...of development, manufacturing and commercialization (see BioCentury, Oct. 13, 2008). Genmab A/S (CSE:GEN), Copenhagen, Denmark TenX Biopharma Inc....
BioCentury | Feb 5, 2010
Company News

TenX in-licenses Genmab's zanolimumab

...Genmab A/S (CSE:GEN) granted TenX Biopharma Inc. (Philadelphia, Pa.) exclusive, worldwide rights to develop and commercialize its zanolimumab...
Items per page:
1 - 9 of 9
BioCentury | Mar 19, 2012
Strategy

Remaking Merck Serono

...non-CTCL Ph III (CTCL); Ph II (non-CTCL) Returned rights in 2007; Genmab out- licensed to TenX Biopharma Inc....
BioCentury | Jun 13, 2011
Company News

Emergent BioSolutions, TenX Biopharma deal

...Emergent received exclusive, worldwide rights to zanolimumab from TenX Biopharma for infectious, cancer and autoimmune indications. TenX...
...under a 2010 deal (see BioCentury, Feb. 8, 2010). Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. TenX BioPharma Inc....
BioCentury | Nov 8, 2010
Strategy

Networking antibodies

...zanolimumab was the oldest and most expensive in use at Genmab. In February, Genmab granted TenX Biopharma Inc....
...NASDAQ:PDLI), Incline Village, Nev. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. TenX Biopharma Inc....
BioCentury | Sep 20, 2010
Clinical News

Zanolimumab: Phase II data

...develop and commercialize zanolimumab from Genmab (see BioCentury, Feb. 8). Genmab A/S (CSE:GEN), Copenhagen, Denmark TenX Biopharma Inc....
BioCentury | Sep 13, 2010
Clinical News

Zanolimumab: Phase III resumed

...and commercialize zanolimumab earlier this year (see BioCentury, Feb. 8). Genmab A/S (CSE:GEN), Copenhagen, Denmark TenX Biopharma Inc....
BioCentury | May 24, 2010
Clinical News

Zanolimumab: Phase II start

...Laboratories Inc. (San Diego, Calif.) markets Proleukin in the U.S. Genmab A/S (CSE:GEN), Copenhagen, Denmark TenX Biopharma Inc....
BioCentury | Feb 8, 2010
Finance

Regulatory milestones

...Pulmagen (see B2) . Genmab A/S (CSE:GEN) lost DKK0.45 to DKK97.50 last week after granting TenX Biopharma Inc....
BioCentury | Feb 8, 2010
Company News

Genmab, TenX Biopharma deal

...of development, manufacturing and commercialization (see BioCentury, Oct. 13, 2008). Genmab A/S (CSE:GEN), Copenhagen, Denmark TenX Biopharma Inc....
BioCentury | Feb 5, 2010
Company News

TenX in-licenses Genmab's zanolimumab

...Genmab A/S (CSE:GEN) granted TenX Biopharma Inc. (Philadelphia, Pa.) exclusive, worldwide rights to develop and commercialize its zanolimumab...
Items per page:
1 - 9 of 9